{"id":"icosema","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Gastrointestinal disorders"}]},"_chembl":{"chemblId":"CHEMBL4594581","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By simultaneously stimulating GLP-1 and GIP receptors, IcoSema enhances insulin secretion in response to glucose, slows gastric emptying, and increases satiety signaling in the brain. This dual mechanism produces greater reductions in blood glucose and body weight compared to single GLP-1 agonists, making it potentially more effective for type 2 diabetes management and weight loss.","oneSentence":"IcoSema is a dual GLP-1/GIP receptor agonist that activates both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors to improve glycemic control and promote weight loss.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:24.755Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Obesity or weight management"}]},"trialDetails":[{"nctId":"NCT05352815","phase":"PHASE3","title":"A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2022-06-01","conditions":"Diabetes Mellitus, Type 2","enrollment":1291},{"nctId":"NCT05013229","phase":"PHASE3","title":"A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-11-30","conditions":"Diabetes Mellitus, Type 2","enrollment":679},{"nctId":"NCT06269107","phase":"PHASE3","title":"A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-02-15","conditions":"Type 2 Diabetes","enrollment":485},{"nctId":"NCT05259033","phase":"PHASE3","title":"A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2022-04-11","conditions":"Diabetes Mellitus, Type 2","enrollment":683},{"nctId":"NCT05435677","phase":"PHASE1","title":"A Research Study to Look at How Insulin Icodec and Semaglutide Work in the Body of People From China With Type 2 Diabetes When Given Alone or Together","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2022-06-22","conditions":"Diabetes Mellitus, Type 2","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":18,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"IcoSema","genericName":"IcoSema","companyName":"Novo Nordisk A/S","companyId":"novo-nordisk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IcoSema is a dual GLP-1/GIP receptor agonist that activates both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors to improve glycemic control and promote weight loss. Used for Type 2 diabetes mellitus, Obesity or weight management.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}